Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1921 + Bevacizumab in TNBC with Brain Metastases
NCT06210438Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tizetatug rezetecan in triple-negative breast cancer (TNBC), sponsored by Fudan University. Primary endpoint: Central Nervous System Objective Response Rate at 24 months. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
tizetatug rezetecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06210438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06210438.